在不同神经学领域使用 vortioxetine:一个系统的审查和未来的前景
Giulio Verrienti1, Isabella Colonna2, Cecilia Raccagni3
1Department of Neurorehabilitation, Casa di Cura Villa Verde, Lecce, 73100, Italy. gverrienti@villaverde.lecce.it.
概括
多种模式抗抑郁药Vortioxetine在改善神经障碍患者的抑郁症状和认知功能方面表现有前途. 需要进一步的研究,以探索其在各种神经疾病中的全部潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 伏尔托克塞丁是一种耐受性良好的多模式抗抑郁药.
- 新出现的证据表明,伏尔西可以增强认知功能,减少与抑郁症相关的残疾.
- 本综述考察了西在各种神经疾病中的应用.
研究的目的:
- 系统地审查在患有神经障碍的患者中使用西的使用情况.
- 综合现有证据,证明伏尔西在脑血管疾病,运动障碍和认知障碍方面的疗效.
主要方法:
- 在PubMed上进行了系统的文献搜索,截至2024年6月.
- 包含的研究是对神经疾病治疗的伏尔西的临床试验,遵守PRISMA指南.
- 通过选引文和参考列表来确定相关的文章.
主要成果:
- 八项研究符合236个初始引用的纳入标准.
- 包含的研究包括3个RCT,1个非随机试验和4个观察性研究.
- 研究被分为脑血管疾病,运动障碍和认知功能障碍.
结论:
- 伏尔托克塞丁在患有并发性神经系统疾病的患者中管理抑郁症状方面表现出潜力.
- 它的亲认知效应表明它可能在治疗患有抑郁症和/或神经认知障碍的成年人中发挥作用.
- 进一步的研究是有必要的,以阐明vortioxetine在神经学中的更广泛的应用.
相关概念视频
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...


